Sutro Biopharma Investor Relations Material

Sutro Biopharma Inc. is a biotechnology company specializing in the discovery, development, and manufacturing of therapeutics aimed at treating cancer. The company leverages its proprietary cell-free protein synthesis platform, XpressCF, to design and produce novel, targeted antibody-drug conjugates (ADCs), bispecific antibodies, and other protein therapeutics. Sutro's focus is on creating therapies that precisely target and eliminate cancer cells while minimizing damage to healthy tissues, advancing treatment options for patients with difficult-to-treat cancers. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.